

Appendix 1

Table 1. Sensitivities and Specificities Reported by Allison 1996

Allison et al.	Hemoccult II [®]	SENSA [®]	HemeSelect [®]
Sensitivity cancer	37.1%	79.4%	68.8%
Specificity cancer	97.7%	86.7%	94.4%
Sensitivity polyp ≥ 1 cm	30.8%	68.6%	66.7%
Specificity polyp ≥ 1 cm	98.1%	87.5%	95.2%

Table 2. Sensitivities and Specificities Reported by Rozen 1997

Rozen et al.	Hemoccult II [®]	SENSA [®]	HemeSelect [®]	FlexSure [®]
Sensitivity adenoma ≥ 1.0 cm or cancer	62.5%	62.5%	86%	62.5%
Specificity adenoma ≥ 1.0 cm or cancer	95%	92%	98%	97%

Table 3. Sensitivities and Specificities Reported by Greenberg 2000

Greenberg et al.	Hemoccult II [®]	SENSA [®]	HemeSelect [®]	FlexSure [®]
Sensitivity cancer	85.7%	78.6%	83.3%	87.5%
Specificity cancer	92.8%	90.5%	88.2%	86.2%
Sensitivity adenoma ≥ 10 mm	20.5%	35.9%	37.1%	35.9%
Specificity adenoma ≥ 10 mm	91.5%	90.7%	88.3%	85.6%

Table 4. Participation Rates Reported by Cole 2003

Cole et al.	IFOBT combined	gFOBT
Sample size	1212	606
Returned test	425	142
Participation rate	35%	23%